Immunotherapy for Metastatic Melanoma — PD-1 Clinical Trials MelanomaReAlli 2024-05-05 | Immunotherapy for Metastatic Melanoma — PD-1 Clinical Trials
Bimini Bay Outfitters x Melanoma Research Alliance Partnership: Veterans Day Update MelanomaReAlli 2023-11-16 | On November 9th, MRA’s Stephanie Kauffman & Bimini Bay’s Christian Parisi went live to discuss the MRAxBBO partnership and some of the innovative work MRA supports focused on Veterans & members of the U.S. Armed Forces.
Military Service and Melanoma Risk: A Conversation with MRA and Army Veteran Andrew Smith MelanomaReAlli 2023-11-10 | Research shows that U.S. military personnel are at higher risk of developing melanoma. We also know that veterans are more likely to be diagnosed with melanoma after it has already progressed to stage 3 or 4, when it is far harder to treat and cure. This is likely due to several factors, such as exposure to high levels of UV radiation during military service, lack of access to regular skin screenings, and delayed diagnosis and treatment.On November 10th, MRA's CEO Dr. Marc Hurlbert and Army Veteran and melanoma survivor Andrew Smith joined together for a special discussion about melanoma risk in the military and veteran community. You’ll also hear about innovative research MRA is leading in partnership with the United States Departments of Defense (DOD) and Veterans Affairs (VA) to identify risk factors for rare melanomas by examining anonymized health records of those treated at VA hospitals over the past 20 years.
What Veteran's Day Means to MRA - Nico Starink MelanomaReAlli 2023-11-08 | MRA asked its staff to share what Veteran's Day means to them, and this is Nico Starink's answer.
What Veteran's Day Means to MRA - Laurel Farr MelanomaReAlli 2023-11-08 | MRA asked its staff to share what Veteran's Day means to them, and this is Laurel Farr's answer.
What Veteran's Day Means to MRA - Marc Hurlbert MelanomaReAlli 2023-11-06 | MRA asked its staff to share what Veteran's Day means to them, and this is Marc Hurlbert's answer.
What Veteran's Day Means to MRA - Janine Rauscher MelanomaReAlli 2023-11-06 | MRA asked its staff to share what Veteran's Day means to them, and this is Janine Rauscher's answer.
What Veteran's Day Means to MRA - Cody Barnett MelanomaReAlli 2023-11-06 | MRA asked its staff to share what Veteran's Day means to them, and this is Cody Barnett's answer.
What to Expect from a Sentinel Lymph Node Biopsy MelanomaReAlli 2023-10-04 | Hear from Charlotte Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center & MRA Funded Investigator and Advisor – as she explains what a sentinel lymph node biopsy is and its role in the staging of melanoma.
Mohs Surgery for Melanoma In Situ MelanomaReAlli 2023-10-04 | Hear from Charlotte Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center & MRA Funded Investigator and Advisor – as she explains what a mohs surgery is and its role in the treatment of melanoma in situ (stage 0).
What is a Wide Local Excision Surgery for Melanoma? MelanomaReAlli 2023-10-04 | Hear from Charlotte Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center & MRA Funded Investigator and Advisor – as she explains what a wide local excision surgery is and its role in the treatment of melanoma.
The Role of Surgery in Melanoma Treatment MelanomaReAlli 2023-10-03 | Hear from Charlotte Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center & MRA Funded Investigator and Advisor – as she explains the important role of surgery in the treatment of melanoma.
The Truth About Placebos in Melanoma Clinical Trials MelanomaReAlli 2023-09-29 | Hear from Dr. Sapna Patel as she answers one of the most common questions she's asked about clinical trials: 'Is there a placebo?'
The Melanoma Staging System MelanomaReAlli 2023-09-29 | Learn about the melanoma staging system from Charlotte Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center & MRA Funded Investigator and Advisor.
Sun Safety Tips to Prevent Melanoma MelanomaReAlli 2023-09-29 | Hear from MRA-funded investigator Dr. Maria Wei on sun safety tips that can help lower your risk of melanoma.
What is Uveal Melanoma? MelanomaReAlli 2023-09-29 | Uveal melanoma, sometimes called ocular melanoma, is a type of cancer that affects the uvea, the middle layer of the eye that contains blood vessels, pigment cells (melanocytes), and provides nutrients and oxygen to the retina. It is a rare form of melanoma derived from the melanocytes in the uvea, accounting for only about 5% of all cases of melanoma in the United States.Learn more at www.curemelanoma.org
What is Mucosal Melanoma? MelanomaReAlli 2023-09-29 | Mucosal melanoma is a rare form of melanoma that develops in the mucous membranes of the body, such as those lining the mouth, nose, throat, anus, or genital areas. It is different from cutaneous melanoma, which develops in the skin.Learn more at www.curemelanoma.org
What is Acral Melanoma? MelanomaReAlli 2023-09-29 | Acral melanoma, sometimes called acral lentiginous melanoma, is a rare subtype of melanoma that forms on the palms, soles of feet, or under finger or toe nails. Unlike cutaneous (skin) melanoma, it is not believed to be caused by sun exposure and therefore occurs in areas not typically exposed to the sun. Acral melanoma affects people of all races and ethnicities.Learn more at www.curemelanoma.org
RARE Registry Update: August 2023 MelanomaReAlli 2023-08-23 | During this RARE Registry update, held on August 23 at 12:30 pm ET, de-identified data was shared from the first 100 participants, new participant features were demonstrated, and the MRA team answered questions from participants. Learn more about the RARE Registry at www.raremelanoma.org
Strategies for Success in Securing CDMRP Funding MelanomaReAlli 2023-08-01 | During this interactive discussion hosted by Melanoma Research Alliance, you'll learn about - and get tips for securing funding from - the U.S. Department of Defense Melanoma Research Program.Dr. Amie Bunker, Program Manager of the Melanoma Research Program will introduce the CDMRP, MRP, and the currently available funding opportunities. Dr. Genevieve Boland of Massachusetts General Hospital will share insight and experiences as a recipient of the CDMRP Program Award for Rare Melanomas. Dr. Bin Zheng of Cedars-Sinai Cancer Institute will also share his application experience as a CDMRP Mid-Career Accelerator awardee.*Opinions, interpretations, conclusions and recommendations are those of the speakers and are not necessarily endorsed by the Department of the Army or the Department of Defense.
The Melanoma Research Alliance: Advancing Discoveries, Changing Lives, & Curing Melanoma MelanomaReAlli 2023-06-26 | Learn more about the Melanoma Research Alliance (MRA), the world’s largest private nonprofit funder of melanoma research. MRA has directly invested over $150 million toward scientific discoveries, and we won’t stop until we achieve our mission of curing melanoma.MRA funds the brightest, boldest, and most promising melanoma skin cancer research worldwide while supporting patients and families every step of the way.MRA is the largest, most effective organization laser-focused on curing melanoma. And, thanks to the ongoing generosity of our founders, 100% of all donations are invested directly to a future MRA grant award.
Advancing Discoveries, Changing Lives, & Curing Melanoma MelanomaReAlli 2023-06-22 | Learn more about the Melanoma Research Alliance (MRA), the world’s largest private nonprofit funder of melanoma research. MRA has directly invested over $150 million toward scientific discoveries, and we won’t stop until we achieve our mission of curing melanoma.MRA funds the brightest, boldest, and most promising melanoma skin cancer research worldwide while supporting patients and families every step of the way.MRA is the largest, most effective organization laser-focused on curing melanoma. And, thanks to the ongoing generosity of our founders, 100% of all donations are invested directly to a future MRA grant award.
2023 Step Up for Melanoma Kick Off MelanomaReAlli 2023-04-28 | Step Up for Melanoma Research is a virtual community-building, fundraising, and awareness campaign that challenges participants to walk 10,000 steps a day, every day, to benefit the Melanoma Research Alliance throughout Melanoma Awareness Month in May.Best of all, 100% of every dollar raised will go directly to research, without any admin or other fees.This kickoff webinar includes MRA's CEO Dr. Marc Hurlbert, MRA's President & COO Stephanie Kauffman, MRA's Chief Science Officer Dr. Joan Levy, and melanoma patient advocate Trena Brown.Learn more and register for Step Up for Melanoma at www.curemelanoma.org/stepup
Living with Melanoma in 2023: A Panel Discussion MelanomaReAlli 2023-03-15 | This discussion, led by MRA's Chief Science Officer Dr. Joan Levy, features perspectives from three patient advocates about their journey with melanoma. This talk was given as part of the Melanoma Research Alliance's 2023 Melanoma Exchange Patient Forum held on March 8, 2023. MRA’s Melanoma Exchange Patient Forum, brings together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Maximizing Your Quality of Life Despite Melanoma MelanomaReAlli 2023-03-15 | During this exciting panel led by MD Anderson Cancer Center's Dr. Lorenzo Cohen, Stanford University's Dr. Allison Betof Warner, Oregon Health & Science University's Dr. Alexender Witowski, and patient advocate Bill Evans, you'll learn how managing stress, eating a healthy diet, good sleep, and staying active can help improve your quality of life despite melanoma. You’ll also hear about exciting advances in non-invasive imaging that could make skin biopsies a thing of the past.This talk was given as part of the Melanoma Research Alliance's 2023 Melanoma Exchange Patient Forum held on March 8, 2023. MRA’s Melanoma Exchange Patient Forum, brings together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Lost in Translation: Improving Communication With Your Care Team MelanomaReAlli 2023-03-14 | Throughout your journey with melanoma, few relationships are more important than the bond between you and your doctor. You are a team, and teams work best when the communication flows freely in both directions. As a patient, you want care that is not only tailored to the unique feature of your disease but also to your personal needs. For example, do you want your doctor to explain the science – or reasoning - behind each procedure? How active do you want to be in making care decisions? Learning how to communicate effectively with your doctor and care team, set expectations, and to prepare for each appointment are important strategies to help you make the most out of each visit with your care provider. This panel, led by Weil Cornell’s Dr. Anna Pavlick and melanoma patient advocates Kristina Baum and Nadia Jabri, makes the case for why good communication matters AND more importantly, will offer you concrete tips, tricks, and strategies to make sure that you’re being a proactive partner with your care team.
Melanoma and Brain Metastases MelanomaReAlli 2023-03-14 | Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. This talk, led by The Angeles Clinic's Dr. Omid Hamid, explains what leptomeningeal disease (LMD) and brain metastases (mets) are, how they are currently being treated, and explores ongoing research.This talk was given as part of the Melanoma Research Alliance's 2023 Patient Forum held on March 8, 2023.
How Melanoma is Treated in 2023 MelanomaReAlli 2023-03-14 | Treatment options for patients facing melanoma have dramatically expanded over the last decade. In fact, over the decade alone, 15 new therapeutic options have earned FDA approval and more than 500 clinical trials are actively enrolling patients with melanoma. Patients are living longer, better lives thanks to the power of checkpoint immunotherapies and BRAF/MEK targeted therapies.This talk, led by Georgetown University's Dr. Michael Atkins, overviews the available treatment options for patients facing melnaoma, highlights important unanswered questions, and gives you the information you need to make informed decisions about your care.
Emerging Melanoma Therapies & Clinical Trials to Watch MelanomaReAlli 2023-03-14 | Today, the melanoma research landscape has never been more dynamic. In the last decade alone, 15 new therapeutic options have earned FDA approval and more than 500 clinical trials are actively enrolling patients with melanoma. Patients are living longer, better lives as a result.The downside? It's never been harder for patients, advocates, and doctors alike to keep up. This talk, presented by Dana Farber Cancer Institute's Dr. Elizabeth Buchbinder, overviews emerging melanoma therapies and exciting clinical trials.
2023 Melanoma Exchange Patient & Advocate Forum MelanomaReAlli 2023-03-08 | MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, brings together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provide networking opportunities across the melanoma community.Throughout the event, you’ll hear from leading experts in the melanoma field and have the opportunity to ask questions, discuss, and network with other people who are going through their own melanoma journey. Each session will provide information, insight, and strategies to help navigate melanoma diagnosis, treatment, or beyond.
Melanoma Research Updates December 2022 MelanomaReAlli 2022-12-13 | From promising clinical trial results to new treatment approaches and an evolving standard of care, 2022 has proven to be an exciting year of advances in melanoma research. Melanoma Research Alliance CEO Marc Hurlbert, Ph.D., and Senior Director of Special Projects Joan Levy, Ph.D., discuss recent melanoma research advances and answered audience questions in this interactive discussion.
Securing CDMRP Funding - Tips from the Melanoma Research Alliance MelanomaReAlli 2022-08-05 | The U.S. Department of Defense Melanoma Research Program (MRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), is committed to diminishing the disease burden of melanoma on service members, veterans, and the general population. In Fiscal Year 2022 (FY22), the Melanoma Research Program intends to award a total of $40 million in melanoma research funds. To support researchers in applying for - and securing - support from CDMRP, the Melanoma Research Alliance held a webinar discussion on August 4, 2022. The discussion featured: • Marc Hurlbert, PhD, MRA Chief Executive Officer, who shared an overview of the CDMRP Melanoma Research Program and its FY22 funding opportunities; • Andrew Aplin, PhD (Thomas Jefferson University) who shared insight and experiences as a recipient of multiple grants from the CDMRP; & • Ed Ackerley, Pre Award Program Manager (University of Notre Dame) who shared tips and best practices to support grants administration offices.More information about the program and available funding opportunities is available at: https://cdmrp.army.mil/mrp/default
Adjuvant Therapy for Melanoma MelanomaReAlli 2022-05-23 | In melanoma, adjuvant therapy is sometimes used after surgery to reduce the risk of melanoma returning. Studies have shown that adjuvant therapy for melanoma can reduce the risk of your melanoma returning following surgery by up to 50%. However, adjuvant therapies aren’t without risk and are not appropriate for all patients. It’s important to talk about the possible benefits and risks with your doctor before making any treatment decision.
Step-by-Step: Living with Melanoma: A Panel Conversation MelanomaReAlli 2022-03-16 | This engaging and insightful panel brought together two melanoma survivors and a caregiver to share their experiences and lessons learned throughout their journey with melanoma. The panel addressed topics including discuss issues such as getting up to speed following a life-changing diagnosis, advocating for yourself/loved one, improving communication with your care team, quality of life, and finding community.MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022 brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Staying on the Path: Prevention for the Melanoma Community MelanomaReAlli 2022-03-15 | Led by Tracy Callahan, founder and president of the Polka Dot Mama Melanoma Foundation, this conversation went beyond the basics to get at how people affected by melanoma can keep themselves and their loved ones safe from skin cancer and new melanomas while living life to its fullest. Tracy was joined by Dr. Susan Swetter of Stanford University, Dr. Maria Wei of University of California San Francisco, and Dr. Rachel Vogel from the University of Minnesota.MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022 brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
On the Horizon: Emerging Therapies to Watch MelanomaReAlli 2022-03-15 | Dr. Hussein Tawbi, a physician-scientist at the University of Texas MD Anderson Cancer Center, discusses the incredible progress being made in melanoma research at the 2022 Melanoma Exchange Patient & Advocate Forum.MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022 brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
One Step at a Time: A Melanoma Journey MelanomaReAlli 2022-03-15 | During the 2022 Melanoma Exchange Patient & Advocate Forum, dermatologist Hensin Tsao, surgical oncologist Danielle Bello, and medical oncologist Rodabe Amaria took participants through two hypothetical patient journeys to highlight the importance of multidisciplinary melanoma care teams.And while no two journeys are ever the same, we hope that the experience and insight shared by our expert panel – as well as your own contributions and questions – will help shed some light into the complexities of a melanoma journey from diagnosis, treatment, and beyond.MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022 brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Biomarkers Lighting the Way MelanomaReAlli 2022-03-15 | Dr. David Polsky explains what biomarkers are and how they can help patients facing melanoma at the 2022 Melanoma Exchange Patient & Advocate Forum. MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022 brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Opening Remarks - 2022 Melanoma Exchange Patient Forum MelanomaReAlli 2022-03-15 | Opening remarks from the 2022 Melanoma Exchange Patient Forum delivered by MRA President & CEO Michael Kaplan and Director of Communications & Patient Engagement Cody Barnett.MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
Dr. Michael Atkins on Immunotherapy or Targeted Therapy as First Treatment for Advanced Melanoma MelanomaReAlli 2022-02-02 | While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins, Chair of MRA’s Medical Advisory Panel, provides practice-changing insight.
LFFM 2021 MelanomaReAlli 2021-10-04 | More than 750 people – representing more than 80 firms from across the leveraged finance and private equity communities – came together at the Museum of Modern Art for the tenth annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. The event raised more than $2.4 million for the Melanoma Research Alliance lifesaving research program.
Laying the Groundwork for Patient-Centric Research MelanomaReAlli 2021-08-04 | MRA's Senior Director of Scientific Program Kristen Mueller hosts conversation between Rising Tide Foundation for Clinical Cancer Research's Senior Scientific Program Manager Alexandre Alencar, and melanoma survivor and patient advocate T.J. Sharpe discuss the importance of patient centricity in clinical research.This video provides examples and gives context to upcoming requirements to apply for a special opportunity supported by MRA and RTFCC that will be released in early September.The special opportunity is anticipated to support up to $1.5 million for each of the two awards, over a five-year period. Critical to these opportunities will be a patient-centric approach, where patients are engaged early on, and throughout the project in designing/refining/and guiding of such research efforts to ensure patient needs and preferences are front and center.Learn more and subscribe to the RFP at www.curemelanoma.org/RFP
Doubling down on rare Melanomas MelanomaReAlli 2021-05-11 | This panel, including Marc Hurlbert, PhD (MRA), Richard Carvajal, MD (Columbia), Alexander Shoushtari, MD (MSKCC), and Trena Brown (patient advocate) explains 'rare melanomas' and highlights the urgent need for more research not these uncommon melanoma subtypes.
Melanoma & Skin of Color MelanomaReAlli 2021-05-11 | Dr. Susan Taylor (Penn) overviews melanoma among people of color and shares actionable tips for prevention and early diagnosis at MRA's Melanoma Exchange Patient Forum.
Diagnostic Accuracy and the Potential of AI MelanomaReAlli 2021-05-11 | Dr. Joann Elmore (UCLA) answers the question: Can artificial intelligence (AI) help us better diagnose melanoma at its earliest stages? at the MRA Melanoma Exchange Patient Forum a
Surviving and Thriving Despite Melanoma MelanomaReAlli 2021-04-20 | There is life with (and after) melanoma. Hear from four experts about surviving and thriving despite melanoma.
What You Need to Know: Diagnosing Melanoma MelanomaReAlli 2021-04-19 | Dr. Sancy Leachman (OHSU) overviews how dermatologists examine lesions at the visual, cellular, & genetic level to distinguish between healthy moles and possible melanomas.
The Melanoma Treatment & Research Landscape MelanomaReAlli 2021-04-19 | The melanoma treatment landscape has dramatically changed in the last decade & the pace of advancement isn’t slowing down. Hear from MRA-funded investigator, Dr. Evan Lipson (Johns Hopkins University) about what this research means to people facing melanoma.
